Implications of CT imaging for postplan quality assessment in prostate brachytherapy

Brachytherapy

Volumn 11, Issue 6, 2012, Pages 435-440

  Petrik, David ^a   Araujo, Cynthia ^a   Kim, David ^a   Halperin, Ross ^a   Crook, Juanita M ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Brachytherapy; MR CT fusion; Prostate neoplasms; Quality assurance

Indexed keywords

IODINE 125;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DOSIMETRY; EXTERNAL BEAM RADIOTHERAPY; HEALTH CARE QUALITY; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MEDICAL ERROR; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; ORGAN SIZE; PHYSICIAN; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION HAZARD; RADIATION RESPONSE; TREATMENT OUTCOME; TREATMENT PLANNING;

AGED; AGED, 80 AND OVER; BRACHYTHERAPY; BRITISH COLUMBIA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; QUALITY ASSURANCE, HEALTH CARE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, IMAGE-GUIDED; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84868119572     PISSN: 15384721     EISSN: 18731449     Source Type: Journal    
DOI: 10.1016/j.brachy.2012.05.001     Document Type: Article

References (28)

1. Nag S., Bice W., DeWyngaert K., et al. The American Brachytherapy Society recommendations for permanent prostate brachytherapy postimplant dosimetric analysis. Int J Radiat Oncol Biol Phys 2000, 46:221-230.
2. Davis B.J., Horwitz E.M., Lee W.R., et al. American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy. Brachytherapy 2012, 11:6-19.
3. Ho A.Y., Burri R.J., Cesaretti J.A., et al. Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys 2009, 75:16-22.
4. Potters L., Roach M., Davis B.J., et al. Postoperative nomogram predicting the 9-year probability of prostate cancer recurrence after permanent prostate brachytherapy using radiation dose as a prognostic variable. Int J Radiat Oncol Biol Phys 2010, 76:1061-1065.
5. Stone N.N., Stock R.G., Cesaretti J.A., et al. Local control following permanent prostate brachytherapy: Effect of high biologically effective dose on biopsy results and oncologic outcomes. Int J Radiat Oncol Biol Phys 2010, 76:355-360.
6. Stock R.G., Stone N.N., Cesaretti J.A., et al. Biologically effective dose values for prostate brachytherapy: Effects on PSA failure and posttreatment biopsy results. Int J Radiat Oncol Biol Phys 2006, 64:527-533.
7. Potters L., Cao Y., Calugaru E., et al. A comprehensive review of CT-based dosimetry parameters and biochemical control in patients treated with permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2001, 50:605-614.
8. Papagikos M.A., Rossi P.J., Urbanic J.J., et al. A simple model predicts freedom from biochemical recurrence after low-dose rate prostate brachytherapy alone. Am J Clin Oncol 2007, 30:199-204.
9. Zelefsky M.J., Kuban D.A., Levy L.B., et al. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys 2007, 67:327-333.
10. Morris W.J., Keyes M., Palma D., et al. Population-based study of biochemical and survival outcomes after permanent 125I brachytherapy for low- and intermediate-risk prostate cancer. Urology 2009, 73:860-865. discussion 865-867.
11. McLaughlin P.W., Evans C., Feng M., et al. Radiographic and anatomic basis for prostate contouring errors and methods to improve prostate contouring accuracy. Int J Radiat Oncol Biol Phys 2010, 76:369-378.
12. McLaughlin P.W., Crook J.M., Lee W.R., et al. The impact of MRI training on improvement of CT based post-implant dosimetry: A six-physician study. Int J Radiat Oncol Biol Phys 2005, 2:85.
13. Crook J., Borg J., Evans A., et al. 10-Year experience with I-125 prostate brachytherapy at the Princess Margaret Hospital: Results for 1,100 patients. Int J Radiat Oncol Biol Phys 2011, 80:1323-1329.
14. Potters L., Morgenstern C., Calugaru E., et al. 12-Year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol 2005, 173:1562-1566.
15. Stock R.G., Ho A., Cesaretti J.A., et al. Changing the patterns of failure for high-risk prostate cancer patients by optimizing local control. Int J Radiat Oncol Biol Phys 2006, 66:389-394.
16. Sanda M.G., Dunn R.L., Michalski J., et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008, 358:1250-1261.
17. Merrick G.S., Butler W.M., Wallner K.E., et al. Long-term urinary quality of life after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2003, 56:454-461.
18. Merrick G.S., Butler W.M., Tollenaar B.G., et al. The dosimetry of prostate brachytherapy-induced urethral strictures. Int J Radiat Oncol Biol Phys 2002, 52:461-468.
19. Crook J., Fleshner N., Roberts C., et al. Long-term urinary sequelae following 125iodine prostate brachytherapy. J Urol 2008, 179:141-145.
20. Merrick G.S., Butler W.M., Wallner K.E., et al. Erectile function after prostate brachytherapy. Int J Radiat Oncol Biol Phys 2005, 62:437-447.
21. Schiff J.D., Bar-Chama N., Cesaretti J., et al. Early use of a phosphodiesterase inhibitor after brachytherapy restores and preserves erectile function. BJU Int 2006, 98:1255-1258.
22. Stone N.N., Stock R.G. Long-term urinary, sexual, and rectal morbidity in patients treated with iodine-125 prostate brachytherapy followed up for a minimum of 5 years. Urology 2007, 69:338-342.
23. Gomez-Iturriaga Pina A., Crook J., Borg J., et al. Median 5 year follow-up of 125iodine brachytherapy as monotherapy in men aged
24. Sherertz T., Wallner K., Merrick G., et al. Factors predictive of rectal bleeding after 103Pd and supplemental beam radiation for prostate cancer. Brachytherapy 2004, 3:130-135.
25. Pinkawa M., Asadpour B., Piroth M.D., et al. Rectal dosimetry following prostate brachytherapy with stranded seeds-Comparison of transrectal ultrasound intra-operative planning (day 0) and computed tomography-postplanning (day 1 vs. day 30) with special focus on sources placed close to the rectal wall. Radiother Oncol 2009, 91:207-212.
26. Keyes M., Spadinger I., Liu M., et al. Rectal toxicity and rectal dosimetry in low-dose-rate iodine-125 permanent prostate implants: A long-term study in 1006 patients. Brachytherapy 2012, 11:199-208.
27. Snyder K.M., Stock R.G., Hong S.M., et al. Defining the risk of developing grade 2 proctitis following 125I prostate brachytherapy using a rectal dose-volume histogram analysis. Int J Radiat Oncol Biol Phys 2001, 50:335-341.
28. Merrick G.S., Butler W.M., Dorsey A.T., et al. Rectal dosimetric analysis following prostate brachytherapy. Int J Radiat Oncol Biol Phys 1999, 43:1021-1027.